Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
17171
Tickers With News
513
Showing Now
50
Top Ticker
TSLA
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.
Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.
U.S. lawmakers have opened a national security probe into Eli Lilly's (NYSE:LLY) clinical trial activities in China. The House Select Committee on China is seeking detailed information on trial oversight, data access, and ties to Chinese institutions. Lawmakers have set a July 17 deadline for Eli Lilly to respond with documents and explanations. Eli Lilly is a major global pharmaceutical company with a large portfolio across diabetes, obesity, oncology, immunology, and other therapeutic...
Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.
Eli Lilly and Altria stand out as defensive stock ideas as investors weigh a hawkish Fed, a pivotal jobs report and shifting market leadership.
Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY) is $1,349.37, pointing to 12.5% upside from a recent price of $1,199.43. We rate LLY a buy with a 90% confidence score. The GLP-1 franchise is compounding faster than the market appreciated last spring, and Foundayo just opened a scalable oral channel to more than ... Eli Lilly Price Prediction: The Case for Double-Digit Upside
Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.
Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.2% on an annualized basis producing an average annual return of 16.46%. Currently, Eli Lilly has a market capitalization of $1.06 trillion.
Eli Lilly and Company (NYSE:LLY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Eli Lilly and Company (NYSE:LLY) released additional details about the Medicare GLP-1 Bridge program, where it explained how eligible Medicare Part D patients can access its two weight management drugs for a flat $50 per month […]
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios® (abemaciclib) in mainland China:
Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.
Eli Lilly and Company (NYSE:LLY) is one of the Stocks That Will Make You Rich Over the Next 3 Years. Eli Lilly and Company (NYSE:LLY) has gained roughly 6% over the past 30 days, and the Street expects more than 13.6% upside from the current level. Recently, on June 25, Leerink analyst David Risinger raised […]
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.
https://www.cnbc.com/2026/06/29/eli-lilly-regeneron-in-fda-precheck-manufacturing-program.html?&qsearchterm=eli%20lilly
The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.81% change from its previous close.
LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.
Eli Lilly stock surged 7% as healthcare rallies; explore its oncology & neuroscience catalysts, risks from price cuts, and 2026 upsideâClick for more on LLY stock.
Eli Lilly and EZ Corp. lead stocks to watch near buy points this week as investors seek shelter in defensive growth names. The relative strength lines of all top five stocks near buy points are making new highs or near highs. The strong RS lines, which track performance vs. the S&P 500, are especially bullish given the overall uncertain stock market.
Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and BioArctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management […]
Eli Lilly and Company (NYSE:LLY) is one of the safe stocks for beginners to buy in 2026. Eli Lilly and Company (NYSE:LLY) received a rating update from Leerink on June 25. The firm lifted the price target on the stock to $1,232 from $1,119 and maintained an Outperform rating on the shares. In a separate development, […]
Eli Lilly's cancer drug Jaypirca received a positive opinion from the European Medicines Agency regarding its use in chronic lymphocytic leukemia. The opinion supports potential use of Jaypirca across all lines of therapy for CLL in Europe. The recommendation is based on Phase 3 clinical trial data and now moves to European Commission review. Eli Lilly (NYSE:LLY) is best known recently for its GLP-1 portfolio, and oncology remains an important part of the business. The EMA's positive view...
Eli Lilly and Company (NYSE:LLY) is one of the high growth stocks to buy right now. On June 14, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia/CLL […]
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 6.3% in the afternoon session after the European Medicines Agency's committee for human medicines backed its cancer drug, Jaypirca, and the company's popular weight-loss treatments were set for inclusion in a new Medicare program.
Here's what investors should do amid the stock market's divergent signals. Eli Lilly is strong while Tesla EV sales loom.
The pharma titan is expanding into new markets.
Eli Lilly's recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its push into gastrointestinal disease.
Eli Lilly (LLY) became the first pharmaceutical company to cross a $1 trillion market valuation in November last year, carried largely by its highly lucrative obesity and diabetes medications, such as Mounjaro and Zepbound. Now the same demand that built that fortune is creating friction with the ...
These two healthcare leaders have a long history of competing against one another.
It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
Eli Lilly (LLY) combines a perfect 10/10 technical rating with an 8/10 High Growth Momentum score, featuring 113.8% EPS growth and 156% quarterly acceleration within a favorable consolidation setup.
4E Therapeutics, Inc. ("4E"), an Austin-based neuroscience company developing next-generation treatments for chronic pain, today announced that it has been acquired by Eli Lilly and Company ("Lilly").Terms of the
Eli Lilly is acquiring Austin-based 4E Therapeutics, the developer of non-addictive painkillers, for an undisclosed amount.
Eli Lilly and Co (NYSE:LLY) is one of billionaire Ken Fisher’s top high growth stock picks. In the past month, Lilly shares have gained more than 18%. The shares have soared almost 50% over the past year. On June 6, Eli Lilly and Co (NYSE:LLY) presented results from late-stage trials of its weight-loss drug candidate, […]
4E Therapeutics, Inc. ("4E"), an Austin-based neuroscience company developing next-generation treatments for chronic pain, today announced that it has been acquired by Eli Lilly and Company ("Lilly").
Eli Lilly (NYSE:LLY) is acquiring 4E Therapeutics, adding MNK inhibitor candidates aimed at non opioid chronic pain treatment. The deal expands Lilly's neuroscience pipeline beyond its existing focus on metabolic and diabetes therapies. Jaypirca has reached a key clinical milestone in the Phase 3 BRUIN CLL-322 trial in relapsed or refractory chronic lymphocytic leukemia when used with venetoclax and rituximab. These developments represent fresh, material updates for Eli Lilly that relate...
Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.
Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.
Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Dividend Stocks to Buy According to D. E. Shaw. On June 9, Jefferies raised its price recommendation on Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330. It reiterated a Buy rating on the shares. The move followed the release of full data from […]
Eli Lilly’s latest analyst update comes with no changes to the existing price targets, keeping the current benchmarks in place for now. In the sections ahead, you will see how to track these price targets over time and follow the evolving analyst narrative around the stock. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Eli Lilly. Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the...
LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.
FDA approves an extended once-every-eight-weeks maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. The decision expands Eli Lilly's (NYSE:LLY) dermatology footprint beyond its obesity and diabetes drug franchises. Ebglyss already has broad coverage from national pharmacy benefit managers, and the new regimen provides added dosing flexibility for patients. For you as an investor, this FDA decision adds another dimension to Eli Lilly's...
If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.
Eli Lilly and other defensive names gain favor as AI overspending fears spark a sharp rotation out of tech and semiconductor stocks.
Eli Lilly and Company (LLY) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 3:20 PM EDTCompany ParticipantsKenneth Custer -...
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen of one maintenance dose every eight weeks of a single injection (250 mg/2 mL) of EBGLYSS (lebrikizumab-lbkz) for subcutaneous use in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis. EBGLYSS is already approved for a once-monthly maintenance dose, with long-term data showing durable disease control. Now,
FDA approval expands EBGLYSS maintenance dosing to once every eight weeks, offering fewer injections for patients with moderate-to-severe atopic dermatitis.
